title: Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
abstract: OBJECTIVE
  The purpose of this retrospective study was to evaluate the clinical value of serum cytokeratin-19-fragment (cyfra21-1) as a biomarker in nonsmall cell lung cancer (NSCLC).
  
  
  METHODS
  Sixty-six patients with NSCLC and 48 cases with benign lung disease were retrospectively analyzed in the department of thoracic surgery in our hospital. The serum level of cyfra21-1 was detected in the above patients. The diagnosis sensitivity, specificity and the receiver operating characteristic curve were calculated by using the stata11.0 statistical software to evaluate the clinical diagnosis value of serum Cyfra21-1 as NSCLC serologic biomarker.
  
  
  RESULTS
  The mean of serum cyfra21-1 were 8.95 eat. 01 μ/L and 4.28 eat. 89 μ/L in NSCLC patient and control groups respectively, which indicated that the NSCLC group were much higher (P < 0.05). The diagnosis sensitivity and specificity were 77.08% and 63.64% at the threshold of 6.32 μ/L respectively. Moreover, the area under the curve was 0.78 (95% confidence interval: 0.70-0.87).
  
  
  CONCLUSIONS
  Serum cyfra21-1 can be a potential serologic biomarker in evaluation of NSCLC.
authors.forename: Hongjie
authors.initials: H
authors.lastname: Zhao
authors.forename: Xuejun
authors.initials: X
authors.lastname: Shi
authors.forename: Jinbo
authors.initials: J
authors.lastname: Liu
authors.forename: Zhengang
authors.initials: Z
authors.lastname: Chen
authors.affiliation: Department of Thoracic Surgery, Bao Di Hospital, Bao Di Clinical College of Tianjin Medical University, Tianjin 301800, China.
authors.forename: Guangshun
authors.initials: G
authors.lastname: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000175:diagnosis; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D053539:Keratin-19 / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D012984:Software
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D053539:Keratin-19; C102012:antigen CYFRA21.1